双参龙胶囊联合氨氯地平治疗血管痉挛性心绞痛的临床研究

Clinical study of Shuangshenlong Capsules combined with amlodipine in treatment of vasospastic angina

目的探讨双参龙胶囊联合苯磺酸氨氯地平治疗血管痉挛性心绞痛的临床疗效。方法选取2017年3月—2021年3月在天津市宁河区医院心血管内科住院治疗的142例血管痉挛性心绞痛患者,根据随机数字法将142例血管痉挛性心绞痛患者分为对照组和治疗组,每组各71例。对照组患者口服苯磺酸氨氯地平片,5 mg/次,1次/d。治疗组患者在对照组的基础上口服双参龙胶囊,4粒/次,3次/d。两组患者连续服用药物5 d。观察两组临床疗效,比较两组临床症状缓解时间及心绞痛发作情况、血清炎性因子水平。结果治疗后,治疗组患者总有效率是98.59%,显著高于对照组的85.92%(P<0.05)。治疗后,治疗组患者临床出现的胸闷、气短、心前区疼痛缓解时间均显著短于对照组(P<0.05)。治疗后,两组心绞痛持续时间、发作次数均较治疗前显著降低(P<0.05),且治疗后治疗组心绞痛持续时间、心绞痛发作次数低于对照组(P<0.05)。治疗后,两组患者血清白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)、可溶性血管细胞黏附因子-1(sVCAM-1)水平均较治疗前显著降低,但血清基质金属蛋白酶9(MMP-9)水平升高(P<0.05);且治疗后,治疗组患者血清炎性因子水平改善优于对照组(P<0.05)。结论双参龙胶囊联合苯磺酸氨氯地平治疗血管痉挛性心绞痛具有较好的临床疗效,可有效改善患者临床症状,并能降低心绞痛发作次数和炎性反应,值得临床借鉴与推广。

Objective To investigate the curative effect of Shuangshenlong Capsules combined with amlodipine besylate in treatment of vasospastic angina. Methods A total of 142 patients with vasospastic angina who were hospitalized in the Department of Cardiovascular Medicine, Ninghe District Hospital of Tianjin, from March 2017 to March 2021 were selected. According to the random number method, 142 patients with vasospastic angina were divided into control group and treatment group, with 71 cases in each group.Patients in the control group were po administered with Amlodipine Besylate Tablets, 5 mg/time, once daily. Patients in the treatment group were po administered with Shuangshenlong Capsules on the basis of the control group, 4 grains/time, three times daily. Two groups of patients continued to take drugs for 5 d. The clinical efficacy of the two groups were observed, and the relief time of clinical symptoms, angina pectoris attack, and the level of serum inflammatory factors were compared between the two groups. Results After treatment, the total effective rate in treatment group was 98.59%, which was significantly higher than 85.92% in control grou p(P < 0.05). After treatment, the relief time of chest tightness, shortness of breath and precardiac pain in the treatment group was significantly shorter than that in the control group(P < 0.05). After treatment, the duration of angina pectoris and the frequency of angina pectoris in the treatment group were significantly lower than those before treatment(P < 0.05), and the duration of angina pectoris and the frequency of angina pectoris in the treatment group were lower than those in the control group(P < 0.05). After treatment, the levels of serum interleukin-6(IL-6), tumor necrosis factor α(TNF-α) and soluble vascular cell adhesion factor-1(sVCAM-1) in two groups were significantly decreased compared with before treatment, but the level of serum matrix metalloproteinase 9(MMP-9) was increased(P < 0.05). After treatment, the level of serum inflammatory factors in the treatment group was better than that in the control group(P < 0.05). Conclusion Shuangshenlong Capsules combined with amlodipine besylate has a good clinical effect in treatment of vasospastic angina, and can effectively improve the clinical symptoms of patients, and reduce the frequency of angina attack and inflammatory reaction, which is worthy of clinical reference and promotion.